
Southern Europe: Volume drops, value soars

Deal activity remained particularly subdued across Southern Europe in May, although the Rottapharm buyout in Italy sent overall value soaring.
It is too early to tell whether or not the measures enacted to support private equity in Italy, and the path of reforms Spain embarked on, will have a substantial impact on activity in the region.
Deal volumes registered a sharp drop in May, but the overall value invested shot upwards courtesy of Avista and Clessidra: the pair bought a 50% stake in Italian drugmaker Rottapharm, a deal that reportedly values the business at €1.7bn.
Doughty Hanson also did its part in Spain, buying a 40% stake in Quiron Hospitales with the intention of merging the business with its portfolio company USP Hospitales.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater